Developer docs
API playgroundTry for free, no card

Search company profiles

Ethos Discovery

Full company profile

uuid002er5a

Namestring
Ethos Discovery
Legal namestring
Ethos Discovery
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Ethos Discovery is a 501(c)(3) nonprofit scientific incubator founded in December 2016 by clinicians affiliated with Ethos Veterinary Health and headquartered in Westborough, Massachusetts. The organization conducts prospective clinical trials in companion animals with naturally occurring diseases — primarily dogs, cats, and exotic companion mammals — as an alternative to conventional preclinical animal models such as induced-disease mouse studies. Its work is organized across six scientific programs: Hemangiosarcoma, Inflammatory CNS Disease, Innovations in Surgery, Intestinal Dysbiosis, Novel Therapeutics, and Sepsis. Active studies include ETHOS-PUSH (genomically-matched treatment for hemangiosarcoma), CHAMP (hemangiosarcoma molecular profiling identifying four genomic subtypes), MIMIC (minimally invasive metastasectomy for osteosarcoma), Chronic Enteropathy (probiotic therapy), CosMyc 01 (MYC inhibition), STEEP (mesenchymal stem cell therapy for NME in pugs), BONES (osteosarcoma biobanking), and FICUSS (feline idiopathic cystitis).

The business and operating model is grant- and donation-funded rather than commercial. Cash inflows come from philanthropic donations (individuals, foundations, corporations), competitive scientific and small business grants, and in-kind administrative support from Ethos Veterinary Health valued at approximately $1,000,000 per year. The single largest contribution to date is a $10 million donation from National Veterinary Associates (NVA) in August 2022, which seeded the organization's endowment. Per-program annual budgets range from $200,000 to $1,000,000. Pet owners do not pay for clinical trial participation; study-related diagnostics and procedures are covered, and many studies include stipends up to $4,500. Commercial value flows indirectly: results are shared without restriction to parties interested in human health commercialization, and select for-profit partners (e.g., Chou2 Pharma for cannabinoid epilepsy therapeutics; LexaGene for the MiQLab pneumonia diagnostic panel) co-fund or co-develop specific programs.

Ethos Discovery serves three customer segments: pet owners whose animals have conditions matching its scientific priorities; pharmaceutical, biotechnology, and diagnostic developers seeking translational validation; and academic and cross-species researchers. Trial enrollment is generated through the Ethos Veterinary Health hospital network of up to 140 sites across U.S. Pacific, Midwest/Mountain, and East Coast regions, supplemented by an Ambassador program, an online inquiry funnel, and an international collaboration network of more than 50 partners in five countries. Clinical validation outputs include an over-95% post-splenectomy survival rate in prospective HSA trials (vs. historical rates as low as 70%) and a STEEP trial stem-cell response in necrotizing meningoencephalitis.

Short descriptiontext

Ethos Discovery is a 501(c)(3) nonprofit that runs prospective clinical trials in companion animals with naturally occurring diseases across six research programs (hemangiosarcoma, CNS, surgery, dysbiosis, novel therapeutics, sepsis), funded primarily by a $10M NVA endowment and donations, and executed through a network of up to 140 Ethos Veterinary Health hospitals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary clinical research, comparative oncology, clinical trials, translational medicine, veterinary diagnostics
Industry1 code
PRIMARYHLAMANAL
Clinical Research, Trials & Translational Services (Veterinary Regenerative)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Veterinary Clinical Research Services
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Philanthropic Donations
TypeOthers
Description

Tax-deductible donations from private individuals, foundations, and corporations. Donations support clinical research into complex diseases in pets with naturally occurring conditions, administrative and personnel costs, and project funding.

ethosdiscovery.org
2Competitive Scientific and Small Business Grants
TypeOthers
Description

Funding sourced through competitive scientific and small business grant programs, constituting a significant portion of project funding alongside philanthropic donations.

ethosdiscovery.org
3In-Kind Support from Ethos Veterinary Health
TypeOthers
Description

Ethos Veterinary Health provides in-kind donations estimated at $1,000,000 per year supporting administrative functions including legal, compliance, strategic, and operational elements. These seed funds enable other donations to be applied directly to research projects.

ethosdiscovery.org
4Major Endowment Donation
TypeOthers
Description

NVA contributed a $10 million donation to Ethos Discovery, serving as a foundation for the organization's endowment fund and providing significant ongoing funding for research projects.

ethosdiscovery.org
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Others
Pricing details4 tiers
1Free clinical trial participation with all study-related costs covered
ModelOtherBilling cadenceOne time
Notes

All costs for exams and diagnostic tests are fully covered for participating pet owners. For the Chronic Enteropathy study, coverage includes initial and recheck exam fees, all screening diagnostics, endoscopy procedure and biopsies, and Purina HA diet for the study duration (~$8,000 value).

ethosdiscovery.org
2Subsidized or free participation with additional financial incentives
ModelOtherBilling cadenceOne time
Notes

Some studies (e.g., CosMyc, SOLID-Relapse) include additional compensation of up to $1,500-$4,500 for pet owners, particularly when additional biopsies or blood sampling are required beyond standard protocol.

ethosdiscovery.org
3Subsidized surgical study with partial cost coverage
ModelOtherBilling cadenceOne time
Notes

The BONES osteosarcoma study provides ~$5,000 in value covering pre-surgical bloodwork and thoracic radiographs ($1,300 value), $500 credit toward surgery and histopathology, and follow-up thoracic radiographs ($800 per visit every 3 months).

ethosdiscovery.org
4Discounted surgical care for enrolled French Bulldogs
ModelOtherBilling cadenceOne time
Notes

The novel EACA treatment study for French Bulldogs with slipped disc hemorrhage provides free exams, bloodwork, and a $1,500 discount toward MRI, surgery, and hospitalization.

ethosdiscovery.org
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Ethos Discovery is a 501(c)(3) nonprofit scientific incubator that runs prospective veterinary clinical trials in companion animals with naturally occurring diseases across six research programs (Hemangiosarcoma, Inflammatory CNS Disease, Innovations in Surgery, Intestinal Dysbiosis, Novel Therapeutics, and Sepsis). It collaborates with a network of over 50 scientific partners across five countries and leverages up to 140 Ethos Veterinary Health hospitals to enroll patients, collect biospecimens, and validate novel diagnostics and therapeutics intended to benefit both veterinary and human medicine. Clinical study results are provided free of charge and without restriction to parties interested in commercialization for human health.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Over 95% of dogs survived to discharge following splenectomy in Ethos Discovery's prospective hemangiosarcoma trials, compared to historical rates as low as 70%
+5 more records
Product overview1 text field

Ethos Discovery is a 501(c)(3) nonprofit scientific incubator that conducts veterinary clinical research and clinical trials. Rather than a traditional software product company, Ethos Discovery operates research programs across six main scientific areas: Hemangiosarcoma, Inflammatory CNS Disease, Innovations in Surgery, Intestinal Dysbiosis, Novel Therapeutics, and Sepsis. These programs encompass multiple active clinical trials including ETHOS-PUSH for hemangiosarcoma, MIMIC for osteosarcoma, chronic enteropathy studies, and others. The organization collaborates with Ethos Veterinary Health's network of hospitals to conduct studies in pets with naturally occurring diseases, with the goal of developing diagnostics and treatments that benefit both veterinary and human medicine.

Product and service12 records
1Hemangiosarcoma Program
CategoryResearch Program
Description

A scientific program focused on canine hemangiosarcoma, an aggressive cancer in dogs. Includes clinical trials such as ETHOS-PUSH, the CHAMP molecular profiling study, and development of liquid biopsy diagnostics and the STAMP tissue-based molecular prognosis test to enable biologically distinct therapeutic approaches and personalized treatment selection.

2Inflammatory CNS Disease Program
CategoryResearch Program
Description

A research program focused on necrotizing meningoencephalitis (NME) in pugs and other small breed dogs, investigating mesenchymal stem cell therapy (STEEP trial) and genomic markers for early diagnosis and treatment of this inflammatory central nervous system disease.

3Innovations in Surgery Program
CategoryResearch Program
Description

A research program developing and refining minimally invasive surgical techniques (arthroscopy, laparoscopy, thoracoscopy, interventional radiology) to minimize pain, complications, and morbidity while maximizing patient recovery in companion animals.

4Intestinal Dysbiosis Program
CategoryResearch Program
Description

A research program investigating the relationship between intestinal microbiome alterations and non-GI diseases including cancer, immune-mediated conditions, and organ health issues, with goals to develop blood-based diagnostic tests and novel treatments such as a three-microbe probiotic therapeutic.

5Novel Therapeutics Program
CategoryResearch Program
Description

A research program developing novel therapeutics for veterinary medicine, including CBD for epilepsy and improved formulations of mycophenolate and posaconazole, in collaboration with Ethos Compounding Pharmacy.

6Sepsis Program
CategoryResearch Program
Description

A research program focused on improving sepsis diagnosis and prognosis in dogs, including studies on procalcitonin biomarkers and sepsis risk in chemotherapy-induced neutropenia patients.

7ETHOS-PUSH (Precision Medicine Umbrella Study for Hemangiosarcoma)
CategoryClinical Trial
Description

A precision medicine clinical trial evaluating genomically-matched treatments for hemangiosarcoma in dogs. Phase 1 covers hemoabdomen/splenectomy management and Phase 2 covers hemangiosarcoma treatment with novel drugs selected on the basis of tumor molecular subtype from the CHAMP study. Open enrollment to pet owners whose dogs present with splenic tumors and hemangiosarcoma.

8MIMIC (Minimally Invasive Metastasectomy In Canines)
CategoryClinical Trial
Description

A clinical trial investigating minimally invasive surgical treatment (thoracoscopy with miniature chest wall incisions and video camera assistance) for canine osteosarcoma that has metastasized to the lungs, intended to reduce morbidity compared to open thoracotomy.

9Chronic Enteropathy Study
CategoryClinical Trial
Description

A clinical trial comparing diet plus a novel three-microbe probiotic therapy (Peptacetobacter hiranonis, Megamonas funiformis, Enterococcus faecium) versus diet alone for managing chronic enteropathy and diarrhea in dogs. All study-related costs are covered and participants receive a Purina HA diet for the study duration.

10FICUSS Study (Feline Idiopathic Cystitis)
CategoryClinical Trial
Description

A sample collection clinical study to characterize the underlying pathophysiology of feline idiopathic cystitis (FIC), intended to support development of novel diagnostic tests and targeted therapies for the condition.

11BONES (Biobanking Osteosarcoma as a Nexus for Evaluation and Staging)
CategoryClinical Trial
Description

A biobanking study creating a repository of tissue and blood samples from dogs with osteosarcoma to advance bone cancer research in both dogs and humans. Enrolled participants receive approximately $5,000 in value covering pre-surgical bloodwork, thoracic radiographs, surgery/histopathology credits, and follow-up imaging.

12CosMyc 01 (Canine MYC Inhibition Study)
CategoryClinical Trial
Description

A prospective multicenter dose-finding clinical study evaluating the pharmacokinetics and short-term tolerability of OMO-103, a novel peptide MYC inhibitor, in dogs with cancer. Open enrollment with additional study-related compensation for participating pet owners.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-27
Description

Chou2 Pharma partnered with Ethos Discovery to evaluate pharmacokinetics of a potential new proprietary animal drug formulation for treating idiopathic epilepsy in dogs, utilizing Chou2 Pharma's precision cannabinoid formulating platform. A subsequent proof-of-concept efficacy study in dogs with epilepsy is planned. Dr. Khanna leads Ethos Discovery's involvement, with CEO Brian Segebrecht noting the partnership as critical to Chou2 Pharma's goal of treating underserved therapeutic needs in pets.

2Ethos Veterinary Health
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-08-18
Description

Ethos Discovery was created by doctors associated with Ethos Veterinary Health and maintains a close operational relationship. Ethos Veterinary Health provides in-kind donations estimated at $1,000,000 per year covering administrative functions (legal, compliance, strategic, operational). All Board and executive leadership members of Ethos Veterinary Health are individual donors to Ethos Discovery. The hospital network provides access to clinical trials and patients with naturally occurring disease.

ethosdiscovery.org
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-06-01
Description

LexaGene partnered with Ethos Discovery to develop a pneumonia panel to expand the utility of the MiQLab automated multiplex PCR diagnostic instrument in veterinary diagnostics. Ethos Discovery collected respiratory samples and agreed to send them to LexaGene for analytical evaluation of the panel. Ethos Discovery also conducted a clinical evaluation of the pneumonia panel on their purchased MiQLab. Dr. Khanna commented that rapid point-of-care diagnostics would significantly improve outcomes for veterinary patients.

4Vuja De Sciences
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-07
Description

Dr. Chand Khanna, Board Chairman of Ethos Discovery, was appointed to the Board of Directors of Vuja De Sciences, a biotechnology startup developing cancer metastasis treatments. This cross-board relationship connects Ethos Discovery to cutting-edge human cancer drug development efforts.

ethosdiscovery.org
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Contract research organization founded by Ethos Discovery's founder Dr. Chand Khanna, focused on complex medical conditions in pets; operates an overlapping investigator network conducting veterinary clinical trials with industry sponsors.

TypeDirect peer
Description

Long-standing 501(c)(3) nonprofit that funds veterinary and animal health research, including comparative oncology and clinical studies in companion animals; competes for the same donor dollars and scientific priorities.

TypeDirect peer
Description

Veterinary liquid biopsy company whose OncoK9 multi-cancer early detection test for dogs overlaps with Ethos Discovery's planned hemangiosarcoma liquid biopsy and biomarker discovery efforts in canine oncology diagnostics.

TypeDirect peer
Description

Nonprofit funding body that supports canine health research including cancer, immunology, and neurology studies; competing foundation for academic and clinical investigators publishing in the same veterinary research space.

TypeDirect peer
Description

Subsidiary of VolitionRx developing Nu.Q Vet cancer screening and other veterinary diagnostics, directly comparable to Ethos Discovery's diagnostic development programs (e.g., STAMP liquid biopsy, biospecimen biomarker discovery).

TypeDirect peer
Description

Comparative oncology startup running prospective clinical trials in dogs with naturally occurring cancers to inform both veterinary and human oncology drug development; competes directly for the same pharma/biotech translational partner pipeline.

TypeDirect peer
Description

Precision veterinary oncology company offering genomic testing and targeted therapies for dogs with cancer; overlaps on canine cancer molecular subtyping and personalized treatment that Ethos Discovery pursues through CHAMP/ETHOS-PUSH.

TypeBroad incumbent
Description

Part of Mars Petcare, operates the largest U.S. veterinary reference laboratory network serving general practices and specialty hospitals; broad incumbent in the same clinical-diagnostics and biomarker-validation domain.

TypeBroad incumbent
Description

Dominant veterinary diagnostics and reference laboratory company providing in-clinic analyzers and specialty lab services; an established incumbent whose diagnostic and reference lab capabilities overlap with Ethos Discovery's translational diagnostic ambitions.

TypeBroad incumbent
Description

Research and clinical trials arm of the BluePearl specialty and emergency veterinary hospital network; offers a comparable specialty-hospital-driven pipeline for prospective veterinary clinical research.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ethos Discovery

Veterinary Clinical Research Servicesethosdiscovery.org

Ethos Discovery is a 501(c)(3) nonprofit that runs prospective clinical trials in companion animals with naturally occurring diseases across six research programs (hemangiosarcoma, CNS, surgery, dysbiosis, novel therapeutics, sepsis), funded primarily by a $10M NVA endowment and donations, and executed through a network of up to 140 Ethos Veterinary Health hospitals.

What Ethos Discovery does

Ethos Discovery is a 501(c)(3) nonprofit scientific incubator founded in December 2016 by clinicians affiliated with Ethos Veterinary Health and headquartered in Westborough, Massachusetts. The organization conducts prospective clinical trials in companion animals with naturally occurring diseases — primarily dogs, cats, and exotic companion mammals — as an alternative to conventional preclinical animal models such as induced-disease mouse studies. Its work is organized across six scientific programs: Hemangiosarcoma, Inflammatory CNS Disease, Innovations in Surgery, Intestinal Dysbiosis, Novel Therapeutics, and Sepsis. Active studies include ETHOS-PUSH (genomically-matched treatment for hemangiosarcoma), CHAMP (hemangiosarcoma molecular profiling identifying four genomic subtypes), MIMIC (minimally invasive metastasectomy for osteosarcoma), Chronic Enteropathy (probiotic therapy), CosMyc 01 (MYC inhibition), STEEP (mesenchymal stem cell therapy for NME in pugs), BONES (osteosarcoma biobanking), and FICUSS (feline idiopathic cystitis).

The business and operating model is grant- and donation-funded rather than commercial. Cash inflows come from philanthropic donations (individuals, foundations, corporations), competitive scientific and small business grants, and in-kind administrative support from Ethos Veterinary Health valued at approximately $1,000,000 per year. The single largest contribution to date is a $10 million donation from National Veterinary Associates (NVA) in August 2022, which seeded the organization's endowment. Per-program annual budgets range from $200,000 to $1,000,000. Pet owners do not pay for clinical trial participation; study-related diagnostics and procedures are covered, and many studies include stipends up to $4,500. Commercial value flows indirectly: results are shared without restriction to parties interested in human health commercialization, and select for-profit partners (e.g., Chou2 Pharma for cannabinoid epilepsy therapeutics; LexaGene for the MiQLab pneumonia diagnostic panel) co-fund or co-develop specific programs.

Ethos Discovery serves three customer segments: pet owners whose animals have conditions matching its scientific priorities; pharmaceutical, biotechnology, and diagnostic developers seeking translational validation; and academic and cross-species researchers. Trial enrollment is generated through the Ethos Veterinary Health hospital network of up to 140 sites across U.S. Pacific, Midwest/Mountain, and East Coast regions, supplemented by an Ambassador program, an online inquiry funnel, and an international collaboration network of more than 50 partners in five countries. Clinical validation outputs include an over-95% post-splenectomy survival rate in prospective HSA trials (vs. historical rates as low as 70%) and a STEEP trial stem-cell response in necrotizing meningoencephalitis.

Ethos Discovery firmographics

Firmographics
Name
Ethos Discovery
Legal name
Ethos Discovery
Website
https://ethosdiscovery.org
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Ethos Discovery is a 501(c)(3) nonprofit that runs prospective clinical trials in companion animals with naturally occurring diseases across six research programs (hemangiosarcoma, CNS, surgery, dysbiosis, novel therapeutics, sepsis), funded primarily by a $10M NVA endowment and donations, and executed through a network of up to 140 Ethos Veterinary Health hospitals.
Ownership category
akta.pro rank

Ethos Discovery industry classification

Industry
Product category
Veterinary Clinical Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAMANAL
Clinical Research, Trials & Translational Services (Veterinary Regenerative)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals

Keywords

  • Veterinary clinical research
  • Comparative oncology
  • Clinical trials
  • Translational medicine
  • Veterinary diagnostics

Where Ethos Discovery is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ethos Discovery business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Others

Revenue model

  1. Philanthropic Donations: Tax-deductible donations from private individuals, foundations, and corporations. Donations support clinical research into complex diseases in pets with naturally occurring conditions, administrative and personnel costs, and project funding.
  2. Competitive Scientific and Small Business Grants: Funding sourced through competitive scientific and small business grant programs, constituting a significant portion of project funding alongside philanthropic donations.
  3. In-Kind Support from Ethos Veterinary Health: Ethos Veterinary Health provides in-kind donations estimated at $1,000,000 per year supporting administrative functions including legal, compliance, strategic, and operational elements. These seed funds enable other donations to be applied directly to research projects.
  4. Major Endowment Donation: NVA contributed a $10 million donation to Ethos Discovery, serving as a foundation for the organization's endowment fund and providing significant ongoing funding for research projects.

Pricing tiers

ModelBillingPrice
OtherOne timeFree clinical trial participation with all study-related costs covered
OtherOne timeSubsidized or free participation with additional financial incentives
OtherOne timeSubsidized surgical study with partial cost coverage
OtherOne timeDiscounted surgical care for enrolled French Bulldogs

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Ethos Discovery product offering

Product offering

Core offering

Ethos Discovery is a 501(c)(3) nonprofit scientific incubator that runs prospective veterinary clinical trials in companion animals with naturally occurring diseases across six research programs (Hemangiosarcoma, Inflammatory CNS Disease, Innovations in Surgery, Intestinal Dysbiosis, Novel Therapeutics, and Sepsis). It collaborates with a network of over 50 scientific partners across five countries and leverages up to 140 Ethos Veterinary Health hospitals to enroll patients, collect biospecimens, and validate novel diagnostics and therapeutics intended to benefit both veterinary and human medicine. Clinical study results are provided free of charge and without restriction to parties interested in commercialization for human health.

Product overview

Ethos Discovery is a 501(c)(3) nonprofit scientific incubator that conducts veterinary clinical research and clinical trials. Rather than a traditional software product company, Ethos Discovery operates research programs across six main scientific areas: Hemangiosarcoma, Inflammatory CNS Disease, Innovations in Surgery, Intestinal Dysbiosis, Novel Therapeutics, and Sepsis. These programs encompass multiple active clinical trials including ETHOS-PUSH for hemangiosarcoma, MIMIC for osteosarcoma, chronic enteropathy studies, and others. The organization collaborates with Ethos Veterinary Health's network of hospitals to conduct studies in pets with naturally occurring diseases, with the goal of developing diagnostics and treatments that benefit both veterinary and human medicine.

Differentiator

Problem solved

Functional benefit

Products and services

  • Hemangiosarcoma Program A scientific program focused on canine hemangiosarcoma, an aggressive cancer in dogs. Includes clinical trials such as ETHOS-PUSH, the CHAMP molecular profiling study, and development of liquid biopsy diagnostics and the STAMP tissue-based molecular prognosis test to enable biologically distinct therapeutic approaches and personalized treatment selection.
  • Inflammatory CNS Disease Program A research program focused on necrotizing meningoencephalitis (NME) in pugs and other small breed dogs, investigating mesenchymal stem cell therapy (STEEP trial) and genomic markers for early diagnosis and treatment of this inflammatory central nervous system disease.
  • Innovations in Surgery Program A research program developing and refining minimally invasive surgical techniques (arthroscopy, laparoscopy, thoracoscopy, interventional radiology) to minimize pain, complications, and morbidity while maximizing patient recovery in companion animals.
  • Intestinal Dysbiosis Program A research program investigating the relationship between intestinal microbiome alterations and non-GI diseases including cancer, immune-mediated conditions, and organ health issues, with goals to develop blood-based diagnostic tests and novel treatments such as a three-microbe probiotic therapeutic.
  • Novel Therapeutics Program A research program developing novel therapeutics for veterinary medicine, including CBD for epilepsy and improved formulations of mycophenolate and posaconazole, in collaboration with Ethos Compounding Pharmacy.
  • Sepsis Program A research program focused on improving sepsis diagnosis and prognosis in dogs, including studies on procalcitonin biomarkers and sepsis risk in chemotherapy-induced neutropenia patients.
  • ETHOS-PUSH (Precision Medicine Umbrella Study for Hemangiosarcoma) A precision medicine clinical trial evaluating genomically-matched treatments for hemangiosarcoma in dogs. Phase 1 covers hemoabdomen/splenectomy management and Phase 2 covers hemangiosarcoma treatment with novel drugs selected on the basis of tumor molecular subtype from the CHAMP study. Open enrollment to pet owners whose dogs present with splenic tumors and hemangiosarcoma.
  • MIMIC (Minimally Invasive Metastasectomy In Canines) A clinical trial investigating minimally invasive surgical treatment (thoracoscopy with miniature chest wall incisions and video camera assistance) for canine osteosarcoma that has metastasized to the lungs, intended to reduce morbidity compared to open thoracotomy.
  • Chronic Enteropathy Study A clinical trial comparing diet plus a novel three-microbe probiotic therapy (Peptacetobacter hiranonis, Megamonas funiformis, Enterococcus faecium) versus diet alone for managing chronic enteropathy and diarrhea in dogs. All study-related costs are covered and participants receive a Purina HA diet for the study duration.
  • FICUSS Study (Feline Idiopathic Cystitis) A sample collection clinical study to characterize the underlying pathophysiology of feline idiopathic cystitis (FIC), intended to support development of novel diagnostic tests and targeted therapies for the condition.
  • BONES (Biobanking Osteosarcoma as a Nexus for Evaluation and Staging) A biobanking study creating a repository of tissue and blood samples from dogs with osteosarcoma to advance bone cancer research in both dogs and humans. Enrolled participants receive approximately $5,000 in value covering pre-surgical bloodwork, thoracic radiographs, surgery/histopathology credits, and follow-up imaging.
  • CosMyc 01 (Canine MYC Inhibition Study) A prospective multicenter dose-finding clinical study evaluating the pharmacokinetics and short-term tolerability of OMO-103, a novel peptide MYC inhibitor, in dogs with cancer. Open enrollment with additional study-related compensation for participating pet owners.

Quantifiable outcome

  • Over 95% of dogs survived to discharge following splenectomy in Ethos Discovery's prospective hemangiosarcoma trials, compared to historical rates as low as 70%
  • +5 more outcomes

Companies that use Ethos Discovery

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Ethos Discovery technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Ethos Discovery partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, flagship and minor.

  • Chou2 Pharma LLCcoreStrategic or Co-development Partner · 27 January 2025Chou2 Pharma partnered with Ethos Discovery to evaluate pharmacokinetics of a potential new proprietary animal drug formulation for treating idiopathic epilepsy in dogs, utilizing Chou2 Pharma's precision cannabinoid formulating platform. A subsequent proof-of-concept efficacy study in dogs with epilepsy is planned. Dr. Khanna leads Ethos Discovery's involvement, with CEO Brian Segebrecht noting the partnership as critical to Chou2 Pharma's goal of treating underserved therapeutic needs in pets.
  • Ethos Veterinary HealthflagshipStrategic or Co-development Partner · 18 August 2022Ethos Discovery was created by doctors associated with Ethos Veterinary Health and maintains a close operational relationship. Ethos Veterinary Health provides in-kind donations estimated at $1,000,000 per year covering administrative functions (legal, compliance, strategic, operational). All Board and executive leadership members of Ethos Veterinary Health are individual donors to Ethos Discovery. The hospital network provides access to clinical trials and patients with naturally occurring disease.
  • LexaGene Holdings Inc.coreTechnology or Integration · 1 June 2021LexaGene partnered with Ethos Discovery to develop a pneumonia panel to expand the utility of the MiQLab automated multiplex PCR diagnostic instrument in veterinary diagnostics. Ethos Discovery collected respiratory samples and agreed to send them to LexaGene for analytical evaluation of the panel. Ethos Discovery also conducted a clinical evaluation of the pneumonia panel on their purchased MiQLab. Dr. Khanna commented that rapid point-of-care diagnostics would significantly improve outcomes for veterinary patients.
  • Vuja De SciencesminorStrategic or Co-development Partner · 7 January 2019Dr. Chand Khanna, Board Chairman of Ethos Discovery, was appointed to the Board of Directors of Vuja De Sciences, a biotechnology startup developing cancer metastasis treatments. This cross-board relationship connects Ethos Discovery to cutting-edge human cancer drug development efforts.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Ethos Discovery competitors and assessment

Company assessment

Direct peers

  • Animal Clinical Investigation: Contract research organization founded by Ethos Discovery's founder Dr. Chand Khanna, focused on complex medical conditions in pets; operates an overlapping investigator network conducting veterinary clinical trials with industry sponsors.
  • Morris Animal Foundation: Long-standing 501(c)(3) nonprofit that funds veterinary and animal health research, including comparative oncology and clinical studies in companion animals; competes for the same donor dollars and scientific priorities.
  • PetDx: Veterinary liquid biopsy company whose OncoK9 multi-cancer early detection test for dogs overlaps with Ethos Discovery's planned hemangiosarcoma liquid biopsy and biomarker discovery efforts in canine oncology diagnostics.
  • AKC Canine Health Foundation: Nonprofit funding body that supports canine health research including cancer, immunology, and neurology studies; competing foundation for academic and clinical investigators publishing in the same veterinary research space.
  • Volition Veterinary: Subsidiary of VolitionRx developing Nu.Q Vet cancer screening and other veterinary diagnostics, directly comparable to Ethos Discovery's diagnostic development programs (e.g., STAMP liquid biopsy, biospecimen biomarker discovery).
  • One Health Company: Comparative oncology startup running prospective clinical trials in dogs with naturally occurring cancers to inform both veterinary and human oncology drug development; competes directly for the same pharma/biotech translational partner pipeline.
  • FidoCure: Precision veterinary oncology company offering genomic testing and targeted therapies for dogs with cancer; overlaps on canine cancer molecular subtyping and personalized treatment that Ethos Discovery pursues through CHAMP/ETHOS-PUSH.

Broad incumbents

  • Antech Diagnostics: Part of Mars Petcare, operates the largest U.S. veterinary reference laboratory network serving general practices and specialty hospitals; broad incumbent in the same clinical-diagnostics and biomarker-validation domain.
  • IDEXX Laboratories: Dominant veterinary diagnostics and reference laboratory company providing in-clinic analyzers and specialty lab services; an established incumbent whose diagnostic and reference lab capabilities overlap with Ethos Discovery's translational diagnostic ambitions.
  • BluePearl Science: Research and clinical trials arm of the BluePearl specialty and emergency veterinary hospital network; offers a comparable specialty-hospital-driven pipeline for prospective veterinary clinical research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ethos Discovery social profiles

Digital presence

Ethos Discovery financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ethos Discovery leadership team

Management profile

Number of profiles

Profiles11 records

Ethos Discovery funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ethos Discovery M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ethos Discovery

What does Ethos Discovery do?

Ethos Discovery is a 501(c)(3) nonprofit scientific incubator that runs prospective veterinary clinical trials in companion animals with naturally occurring diseases across six research programs (Hemangiosarcoma, Inflammatory CNS Disease, Innovations in Surgery, Intestinal Dysbiosis, Novel Therapeutics, and Sepsis). It collaborates with a network of over 50 scientific partners across five countries and leverages up to 140 Ethos Veterinary Health hospitals to enroll patients, collect biospecimens, and validate novel diagnostics and therapeutics intended to benefit both veterinary and human medicine. Clinical study results are provided free of charge and without restriction to parties interested in commercialization for human health.

Is Ethos Discovery a public or private company?

Ethos Discovery is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Ethos Discovery founded?

Ethos Discovery was founded in 2016. It employs 11 to 50 people.

Where is Ethos Discovery based?

Ethos Discovery is headquartered in San Diego, United States, in the North America region.

How does Ethos Discovery make money?

Four revenue lines are on record. Philanthropic Donations are the primary driver. The others are competitive Scientific and Small Business Grants, in-Kind Support from Ethos Veterinary Health and major Endowment Donation.

Who are Ethos Discovery's main competitors?

Direct peers on record are Animal Clinical Investigation, Morris Animal Foundation, PetDx, AKC Canine Health Foundation, Volition Veterinary, One Health Company and FidoCure. Broad incumbents are Antech Diagnostics, IDEXX Laboratories and BluePearl Science.

Does Ethos Discovery have an API?

No public API is recorded for Ethos Discovery.

What industry is Ethos Discovery in?

Ethos Discovery's product category is Veterinary Clinical Research Services. Its primary akta.pro industry code is HLAMANAL, Clinical Research, Trials & Translational Services (Veterinary Regenerative). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCHOU2 PHARMA Partners with Ethos Discovery to Study Potential New Therapy for Canine Idiopathic EpilepsyChou2 Pharma LLC announced a partnership with Ethos Discovery to study a potential new proprietary cannabinoid-based drug formulation for treating idiopathic epilepsy in dogs, with the pharmacokinetics study scheduled to commence early 2025. The therapy targets a condition affecting dogs where 30-40% are refractory to existing anti-epileptic medications, representing an underserved therapeutic area in veterinary medicine. Chou2 Pharma is simultaneously seeking investment through an open Series A equity financing round and exploring strategic partnerships for co-development and future commercialization.EthosdiscoveryScientific Collaboration in Veterinary ResearchEthos Discovery, a not-for-profit scientific organization, published a call to collaborators inviting clinicians, drug and device developers, diagnostic developers and cross-species scientists to join its veterinary research programs. It reports over 50 ongoing collaborations worldwide and offers study results free of charge to parties interested in human health commercialization. Programs include hemangiosarcoma, inflammatory CNS disease, intestinal dysbiosis, sepsis and novel therapeutics.GlobeNewswireEthos Discovery and Gallant Therapeutics Collaborate on Study Evaluating Gallant’s Stem Cell Therapy in Pugs with Necrotizing Meningoencephalitis (NME), also referred to as Pug Dog Encephalitis (PDE)Ethos Discovery and Gallant Therapeutics announced a collaboration on a third study of Gallant's stem cell therapy for pugs with necrotizing meningoencephalitis (NME). The study uses Gallant's mesenchymal stem cells to treat early-stage NME, aiming to prevent brain damage and improve clinical signs. The trial is part of a program that may inform human trials for similar diseases.GlobeNewswireLexaGene Finalizes Design of Pneumonia PanelLexaGene finalized the design of the MiQLab Pneumonia Panel for companion animals, completed initial multiplex testing, and partnered with Ethos Discovery. The panel includes 13 bacterial, 4 fungal, and 19 antimicrobial resistance assays. Ethos will conduct clinical evaluation on purchased MiQLab instruments.PR NewswireAmericans Are Spending More Than Ever on Pets, Sending the Entire Industry to New HighsAmerican pet spending has more than doubled over the last decade, reaching $103.6 billion in 2020, as millennials drive increased expenditure on pet food, grooming, vet care, insurance, and subscription services. LexaGene Holdings Inc. announced two purchase orders for its MiQLab veterinary diagnostic system from Denver Animal Emergency and Alpine Veterinary Hospital, following the expansion of its sales team and attendance at the ACVIM Forum, while also partnering with Ethos Discovery to expand test menu offerings. Additional pet sector companies including The Original Bark Co., Petmed Express Inc., Zoetis Inc., and Aon PLC reported positive metrics, with the pet care market projected to grow significantly in the coming years.GlobeNewswireLexaGene Partners with Ethos Discovery to Develop New Companion Animal Diagnostic TestsLexaGene partnered with Ethos Discovery to expand the MiQLab system's test menu for companion animals. The first panel detects 94% of UTI pathogens and screens for 13 antimicrobial resistance targets. New panels for pneumonia, diarrhea, and effusions will be developed, with clinical validation starting in late summer/early fall.GlobeNewswireLexaGene Receives Purchase Order for MiQLab from Ethos DiscoveryLexaGene received a purchase order for a MiQLab system from Ethos Discovery. The automated rapid pathogen detection system will be used in veterinary hospitals, with results in about one hour. Ethos plans to expand MiQLab capabilities in 2021.